7 completed, 7 recruiting, 6 terminated, 5 active not recruiting. 18 Phase 1, 8 Phase 3, 7 Phase 2.
Follow Deciphera Pharmaceuticals, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 486 | 2027-01-01 | 2026-09-17 |
| Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants Vimseltinib, Dabigatran - Healthy Male Participants | Phase 1 | Recruiting | Deciphera Pharmaceuticals, LLC | 20 | 2026-09-01 | 2026-09-25 |
| IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Tirabrutinib, Rituximab, Temozolomide - Relapsed/Refractory Primary Central Nervous System Lymphoma | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 132 | 2026-06-12 | 2026-10-20 |
| Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) - Healthy Participants | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 27 | 2026-06-05 | 2026-10-15 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Sapablursen, Placebo - Polycythemia Vera | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 250 | 2026-05-25 | 2026-10-21 |
| Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Vimseltinib, Metformin - Healthy Participants | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 22 | 2025-11-20 | 2026-02-11 |
| Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate Vimseltinib, Rosuvastatin - Healthy Participants | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 20 | 2025-10-31 | 2026-01-15 |
| MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib Tenosynovial Giant Cell Tumor | Recruiting | Deciphera Pharmaceuticals, LLC | 100 | 2025-09-03 | 2026-07-27 | |
| Study of DCC-2812 in Participants With Advanced Genitourinary Cancers DCC-2812 - Renal Cell Carcinoma, Urothelial Carcinoma | Phase 1 | Recruiting | Deciphera Pharmaceuticals, LLC | 60 | 2025-08-27 | 2026-08-18 |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) DCC-3009 - Gastrointestinal Stromal Tumor (GIST) | Phase 1 / Phase 2 | Recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2024-12-10 | 2026-02-05 |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) Vimseltinib - Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Recruiting | Deciphera Pharmaceuticals, LLC | 48 | 2024-11-21 | 2025-12-15 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Ripretinib, binimetinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Withdrawn | Deciphera Pharmaceuticals, LLC | 2021-11-01 | 2022-01-05 | |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor Vimseltinib, Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 123 | 2021-10-14 | 2026-03-20 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST Ripretinib, Repaglinide - GIST - Gastrointestinal Stromal Tumor | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 13 | 2021-09-22 | 2024-09-19 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors Inlexisertib, Trametinib, Binimetinib - Non-Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 91 | 2021-06-15 | 2026-04-08 |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 453 | 2019-02-08 | 2026-10-16 |
Showing 20 of 29. Sign in to see all of them.
Gastrointestinal Stromal Tumors (9) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Giant Cell Tumor of Tendon Sheath (3) · Melanoma (2) · Ovarian Neoplasms (2) · Synovitis, Pigmented Villonodular (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Renal Cell (1)
ripretinib (8) · DCC-2036 (4) · rebastinib (4) · Paclitaxel (2) · Sunitinib (2) · binimetinib (2) · Capecitabine (1) · Carboplatin (1) · Contraceptives, Oral, Combined (1) · DCC-2701 (1) · Dabigatran (1) · Ethinyl Estradiol (1) · Fluorouracil (1) · Leucovorin (1) · Levoleucovorin (1)
United States (25) · Italy (8) · Australia (7) · France (7) · Netherlands (7) · Spain (7) · United Kingdom (7) · Canada (6) · Germany (6) · Poland (6) · Brazil (3) · Norway (3) · Switzerland (3) · Belgium (2) · Chile (2)
B. Douglas Smith, MD (1) · David Snyder, M.D. (1) · Ehab Atallah, MD (1) · H.Jean Khoury, MD (1) · Hedy P Smith, MD (1) · Javier Pinilla-Ibarz, MD,PhD (1) · Jesus D Anampa Mesias, M.D (1) · Jorge Cortes, MD (1) · Kapil Bhalla, MD (1) · Maitreyi Sharma, MD (1) · Moshe Talpaz, MD (1) · Oliver Rosen, M.D. (1) · Richard A Larson, MD (1)
PMID 22825216, PMID 27927766, PMID 31755321, PMID 32511981, PMID 32804590, PMID 34661454, PMID 35947817, PMID 36514034, PMID 37593881, PMID 37598656, PMID 38182785, PMID 38843860, PMID 39229786, PMID 40408605, PMID 42317052
2025 (2)